	US 11,999,771 B2
	IL-7Rαγc ligand immunoglobulin fusion proteins
William J. Dower, Menlo Park, CA (US); Ronald W. Barrett, Menlo Park, CA (US); Michael C. Needels, Menlo Park, CA (US); Steven E. Cwirla, Menlo Park, CA (US); Alice V. Bakker, Menlo Park, CA (US); and Inkyung Park, Menlo Park, CA (US)
Assigned to Medikine, Inc., Menlo Park, CA (US)
Filed by MEDIKINE, INC., Menlo Park, CA (US)
Filed on Dec. 5, 2022, as Appl. No. 18/061,567.
Claims priority of provisional application 63/328,700, filed on Apr. 7, 2022.
Prior Publication US 2023/0322880 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/54 (2006.01); A61K 38/20 (2006.01); A61K 38/00 (2006.01); C07K 7/08 (2006.01); C07K 14/715 (2006.01)

CPC C07K 14/5418 (2013.01) [A61K 38/2046 (2013.01); A61K 38/00 (2013.01); C07K 7/08 (2013.01); C07K 14/7155 (2013.01); C07K 2319/30 (2013.01)]

29 Claims

1. An IL-7Rαγc ligand comprising:

an IL-7Rα ligand comprising an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 1; and

an Rγc ligand comprising an amino acid sequence of SEQ ID NO: 11 or an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 11.